newsfilter
← Latest News
Business Wire·

Maravai LifeSciences Reports First Quarter 2026 Financial Results

First quarter 2026 total revenue up 41% from prior year Base revenue excluding revenue for high-volume CleanCap for commercialized COVID-19 vaccines up 10% from prior year Maravai LifeSciences Holdings, Inc.